SOTIO Biotech a.s. has exercised its first of five exclusive, target-specific options for antibody-drug conjugate (ADC) SOT106 under its agreement with LegoChem Biosciences Inc.
https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2022-11-29_um_18.21.05.png540960Margarita Milidakis/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMargarita Milidakis2022-11-29 17:50:012024-07-16 12:13:01SOTIO licences first cancer ADC from LegoChem Biosciences